M
Matthew P. Patricelli
Researcher at Scripps Research Institute
Publications - 58
Citations - 8238
Matthew P. Patricelli is an academic researcher from Scripps Research Institute. The author has contributed to research in topics: Kinase & Fatty acid amide hydrolase. The author has an hindex of 31, co-authored 55 publications receiving 7237 citations. Previous affiliations of Matthew P. Patricelli include McGill University & Torrey Pines Institute for Molecular Studies.
Papers
More filters
Journal ArticleDOI
Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase
Benjamin F. Cravatt,Kristin Demarest,Matthew P. Patricelli,Michael H. Bracey,Dan K. Giang,Billy R. Martin,Aron H. Lichtman +6 more
TL;DR: Results indicate that FAAH is a key regulator of anandamide signaling in vivo, setting an endogenous cannabinoid tone that modulates pain perception, and may represent an attractive pharmaceutical target for the treatment of pain and neuropsychiatric disorders.
Journal ArticleDOI
Activity-based protein profiling: The serine hydrolases
TL;DR: The chemical synthesis and utility of an active-site directed probe for visualizing dynamics in the expression and function of an entire enzyme family, the serine hydrolases, is described and it is shown that FP-biotin labels these proteins in an activity-dependent manner that can be followed kinetically.
Journal ArticleDOI
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
Matthew R. Janes,Jingchuan Zhang,Lian-Sheng Li,Rasmus Hansen,Ulf Peters,Xin Guo,Yuching Chen,Anjali Babbar,Sarah J. Firdaus,Levan Darjania,Jun Feng,Jeffrey H. Chen,Shuangwei Li,Shisheng Li,Yun O. Long,Carol Thach,Yuan Liu,Ata Zarieh,Tess Ely,Jeff Kucharski,Linda Kessler,Tao Wu,Ke Yu,Yi Wang,Yvonne Yao,Xiaohu Deng,Patrick P. Zarrinkar,Dirk Brehmer,Dashyant Dhanak,Matthew V. Lorenzi,Dana D. Hu-Lowe,Matthew P. Patricelli,Pingda Ren,Yi Liu +33 more
TL;DR: This study provides in vivo evidence that mutant KRAS can be selectively targeted and reveals ARS-1620 as representing a new generation of KRASG12C-specific inhibitors with promising therapeutic potential.
Journal ArticleDOI
Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.
Matthew P. Patricelli,Matthew R. Janes,Lian-Sheng Li,Rasmus Hansen,Ulf Peters,Linda Kessler,Yuching Chen,Jeff Kucharski,Jun Feng,Tess Ely,Jeffrey H. Chen,Sarah J. Firdaus,Anjali Babbar,Pingda Ren,Yi Liu +14 more
TL;DR: ARS-853 is described, a selective, covalent inhibitor of KRAS(G12C) that inhibits mutant KRAS-driven signaling by binding to the GDP-bound oncoprotein and preventing activation.
Journal ArticleDOI
Functional interrogation of the kinome using nucleotide acyl phosphates.
Matthew P. Patricelli,A. Katrin Szardenings,Marek Liyanage,Tyzoon K. Nomanbhoy,Min Wu,Helge Weissig,Arwin Aban,Doris Pik-Yiu Chun,Stephen Tanner,John W. Kozarich +9 more
TL;DR: A method for identifying and quantifying protein kinases in any biological sample or tissue from any species using acyl phosphate-containing nucleotides and direct competition between probes and inhibitors can be assessed to determine inhibitor potency and selectivity against nativeprotein kinases, as well as hundreds of other ATPases.